INBRX-105
PD-L1x4-1BB bispecific for solid tumors
Key Facts
About Inhibrx Biosciences
Inhibrx leverages its proprietary sdAb platform to create differentiated, multi-specific protein therapeutics designed to overcome the limitations of conventional antibodies. The company's pipeline includes multiple clinical-stage assets targeting oncology and rare diseases, with strategic partnerships in place with major pharmaceutical companies. Inhibrx's approach focuses on optimizing pharmacokinetics, tissue penetration, and manufacturability to develop best-in-class therapies for complex biological targets.
View full company profile